11 completed. 7 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 1 | Completed 1 |
Follow Clavis Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacytarabine Mass Balance Study in Healthy Volunteers [14C]-Elacytarabine - Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects | Phase 1 | Completed | Clavis Pharma | 6 | 2013-02-01 | 2013-08-28 |
| The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055) Elacytarabine for infusion - Relapsed/Refractory AML | Phase 1 | Completed | Clavis Pharma | 43 | 2010-10-01 | 2013-09-23 |
| Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) Elacytarabine, Investigator's Choice - Acute Myeloid Leukemia (AML) | Phase 3 | Completed | Clavis Pharma | 381 | 2010-06-01 | 2013-09-27 |
| A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia Elacytarabine plus idarubicin - Acute Myeloid Leukemia | Phase 2 | Completed | Clavis Pharma | 51 | 2009-12-01 | 2013-09-27 |
| A Study of CP-4126 in Patients With Advanced Pancreatic Cancer IV CP-4126 - Advanced Adenocarcinoma of Pancreas | Phase 2 | Completed | Clavis Pharma | 21 | 2009-04-01 | 2012-02-10 |
| A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour CP-4126, Gemcitabine - Solid Tumors | Phase 1 | Completed | Clavis Pharma | 26 | 2008-10-01 | 2010-09-06 |
| A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer CP-4055 - Ovarian Cancer | Phase 1 / Phase 2 | Completed | Clavis Pharma | 28 | 2008-04-01 | 2013-09-13 |
| A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer CP-4055 - Advanced Colorectal Cancer, Colorectal Cancer | Phase 2 | Completed | Clavis Pharma | 16 | 2007-05-01 | 2009-06-04 |
| Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma CP-4055, Sorafenib (Nexavar) - Malignant Melanoma | Phase 2 | Completed | Clavis Pharma | 18 | 2007-03-01 | 2013-09-12 |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies CP-4055 - Hematologic Malignancies, AML | Phase 1 / Phase 2 | Completed | Clavis Pharma | 153 | 2006-05-01 | 2013-09-18 |
| Clinical Study of Previously Untreated Patients With Malignant Melanoma CP-4055 (ELACYT) - Malignant Melanoma, Neoplasm Metastasis | Phase 2 | Completed | Clavis Pharma | 42 | 2005-09-01 | 2007-07-10 |
Neoplasms (6) · Neoplasm Metastasis (4) · Leukemia, Myeloid, Acute (3) · Melanoma (2) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia (1) · Ovarian Neoplasms (1) · Recurrence (1)
5'-oleoyl cytarabine (9) · CP 4126 (2) · Gemcitabine (1) · Idarubicin (1) · Sorafenib (1)
Norway (6) · United Kingdom (5) · United States (5) · Belgium (4) · France (3) · Germany (3) · Italy (3) · Spain (2) · Sweden (2) · Australia (1) · Canada (1) · Ireland (1) · Netherlands (1) · Poland (1) · Romania (1)
Ahmad H Awada, MD (1) · David A Rizzieri, MD (1) · David Rizzieri, MD (1) · Francis J Giles, MD (1) · Francis J Giles, MD, PhD (1) · Jim Cassidy, MBChB, MD (1) · Sandro Pignata, MD (1) · Steven Knapper, MD (1) · Svein Dueland, MD (1) · Svein Dueland, MD, Ph.D (1)